# Glucagon Receptor Mechanism: Enhancing Energy Expenditure and Reducing Hepatic Fat

Canonical source: https://retacompare.com/research/glucagon-receptor-mechanism-energy-expenditure-and-hepatic-effects

Receptor Mechanisms · 2026-05-02


    Glucagon plays a crucial role in increasing resting energy expenditure and reducing hepatic fat, making it a key target in next-generation multi-agonist obesity and metabolic drugs following Retatrutide's development.

 The big picture

Following the introduction of Retatrutide, a multi-agonist that targets GLP-1, GIP, and glucagon receptors, the pharmaceutical landscape is poised for further exploration of glucagon's role in metabolic regulation. The ongoing interest in multi-agonist therapies stems from their potential to address obesity and related metabolic disorders more effectively than traditional single-target agents. As obesity rates continue to rise globally, there is a pressing need for innovative therapies that can enhance energy expenditure and improve liver function, both of which are influenced by glucagon signaling.

 How it works

Glucagon exerts its effects primarily through the glucagon receptor (GCGR), which is predominantly expressed in the liver but also found in other tissues such as adipose tissue and the pancreas. Activation of GCGR leads to increased hepatic glucose production and enhanced lipolysis, but it also plays a critical role in energy expenditure. By stimulating thermogenesis in brown adipose tissue and promoting uncoupling protein expression, glucagon can increase resting energy expenditure. In the context of multi-agonist designs, combining glucagon with GLP-1 and GIP may synergistically enhance metabolic outcomes, potentially leading to greater weight loss and improved liver health.

 Key points at a glance

Glucagon receptor activation increases resting energy expenditure.

It reduces hepatic fat accumulation via enhanced lipolysis and improved glucose metabolism.

Next-generation multi-agonists aim to combine glucagon with other incretin hormones.

Potential candidates in development include HM15275, MariTide, and Survodutide.

Clinical data on these agents remain limited but show promise in early studies.

Multifaceted approaches may address obesity and metabolic disorders more effectively.

Research continues to elucidate the full therapeutic potential of glucagon in these combinations.

 Where this fits in the pipeline

Several companies are actively developing multi-agonist therapies that incorporate glucagon. For instance, Hanmi's HM15275 and Amgen's MariTide are in various stages of clinical trials, while Boehringer's Survodutide is also being evaluated for its metabolic effects. These agents are designed to leverage the benefits of glucagon alongside other incretin hormones. While some early data suggest favorable outcomes, comprehensive results are still pending, and the precise efficacy of these combinations remains to be fully established.

 What it could mean for patients

If successful, multi-agonist therapies incorporating glucagon could represent a significant advancement in the treatment of obesity and associated metabolic disorders. By enhancing energy expenditure and reducing hepatic fat, these treatments may lead to improved metabolic profiles and potentially lower the risk of comorbidities such as type 2 diabetes and cardiovascular disease. However, the clinical impact will depend on the results of ongoing and future trials, which are essential to determine the safety and efficacy of these novel approaches.

 Open questions and what we don't yet know

Despite the potential of glucagon-based multi-agonist therapies, several questions remain unanswered. The long-term safety of glucagon receptor activation, particularly in combination with other incretin hormones, is still under investigation. Additionally, the optimal dosing strategies and treatment durations are yet to be established. Regulatory pathways for these novel agents also pose challenges, as the complexities of multi-target therapies may require new frameworks for evaluation. Understanding the full scope of glucagon's effects in these contexts is essential for advancing these therapies.

 Bottom line

Glucagon's role in increasing energy expenditure and reducing hepatic fat positions it as a key component in the development of next-generation multi-agonist therapies. Ongoing research will clarify its potential benefits and risks for patients with obesity and metabolic disorders.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources